Innovative Medicines Initiative
|
This article is part of the Pharma_Portal project of Spinwatch. |
History
The Innovative Medicines Initiative (IMI) is a partnership between the European Community and the European Federation of Pharmaceutical Industries and Associations (EFPIA). According to its website: 'The objective of IMI is to support the faster discovery and development of better medicines for patients and to enhance Europe’s competitiveness by ensuring that its biopharmaceutical sector remains a dynamic high-technology sector.'[1]
Achieving the Objectives
- The European Commission and EFPIA propose to create and operate a new Public Private Partnership, the IMI Joint Undertaking, which will fund Patient Centred Projects.
- These Patient Centred Projects will consider delays in the process of getting new drugs on the market and address these issues in order to speed up the process.
- Patient Centred Projects will be conducted with European patient organisations, universities, hospitals, regulatory authorities, and small and large companies.[2]
- Representatives from the pharmaceutical industry, patient groups, universities, regulatory authorities and hospitals will collaborate to form the IMI Strategic Research Agenda which will: predict the safety and efficacy of drugs; and bridge gaps in knowledge management, education and training.[3]
People
From the industry side:[4]
- Brian Ager (EFPIA Director General)
- Andreas Busch (Head of Global Drug Discovery, Bayer HealthCare)
- Jackie Hunter (Senior Vice President, GlaxoSmithKline R&D)
- Carlo Incerti (Head of R&D Europe & Co-Chair of European Management Board, Genzyme)
- Jonathan Knowles (President of Group Research, F. Hoffmann-La Roche)
From the European Commission:
- Daniel Jacob (DG Research, Deputy Director-General)
- Ruxandra Draghia-Akli (DG Research, Director)
- Franco Biscontin (DG Research, Director)
- Georgette Lalis (DG Enterprise, Director)
- Andrzej Jan Rys (DG Sanco, Director)
Funding
- Pharmaceutical companies fund their own participation - 100%.
- Pharmaceutical companies provide R&D resources such as staff, laboratory facilities, materials and clinical research.
- Through the EFPIA, companies will fund half of the cost of the IMI Executive Office - about 4% of the total budget.
- Public money will go exclusively to other participants (public sector, SMEs, patient groups, academics.[5]
Contact
- Address:
- IMI
- c/o EFPIA
- Leopold Plaza Building
- Troonstraat
- Rue du Trône 108
- B-1050
- Brussels
- Belgium
- Website:
- http://www.efpia.org
Notes
- ↑ IMI. IMI Objectives Accessed on 9 May 2009
- ↑ IMI. IMI Objectives Accessed on 9 May 2009
- ↑ IMI. IMI Objectives Accessed on 9 May 2009
- ↑ IMI. IMI Governance Accessed on 9 May 2009
- ↑ IMI.IMI Funding. Accessed on 9 May 2009.
